Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
LCLineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc. (LCTX)

New York Stock Exchange Arca · Currency in USD
$0.99 ▼ -0.01 (-0.81%)
As of Oct 26, 12:32 PM ET. Market open.

Summary

Previous Close
$1.00
Open
$1.00
Day's Range
$0.97 – $1.01
52 Week Range
$0.88 – $2.09
Volume
746,357
Avg. Volume
1,422,409
Market Cap
$250.86M
Beta (5Y Monthly)
1.60
PE Ratio (TTM)
--
EPS (TTM)
-$0.13
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Dec 15, 2003
1y Target Est
--

Profile: Lineage Cell Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
75
CEO
Brian Culley

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.02 · Revenue est. $2.32M
DateEst.Actual
Aug 6, 2026-$0.03-$0.03Miss
May 12, 2026-$0.02-$0.03Miss
Mar 5, 2026-$0.04$0.00Beat
Nov 6, 2025-$0.02-$0.13Miss
Aug 12, 2025-$0.02-$0.01Beat
May 13, 2025-$0.02-$0.02Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Similar stocks

Get free alerts on LCTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.